White House Pulls Heidi Overton's FDA Commissioner Nomination

The White House has withdrawn Heidi Overton's nomination to lead the FDA, citing insufficient support in the Senate, according to administration officials and people familiar with the decision. The move leaves the agency without a Senate-confirmed permanent commissioner as it pushes through significant staff reductions and advances a broad policy agenda.
Overton, a preventive-medicine physician, was nominated in August following the departure of previous Commissioner Marty Makary. She has served as deputy director of the White House Domestic Policy Council.
A Senate Health, Education, Labor and Pensions Committee vote had been scheduled for Wednesday. Republicans hold only a narrow majority on the panel, which meant a single GOP defection could sink the nomination — a margin that proved too fragile to defend.
What sank the nomination?
Overton faced questioning from both parties during her confirmation process on three flashpoints:
- her positions on vaccines
- abortion policy
- regulation of flavored vaping products
Some Republican senators went further, voicing reservations about her level of experience and her willingness to break from administration positions on certain health issues. Senate HELP Committee Chairman Bill Cassidy later said the White House had abandoned a viable path to confirmation.
Who's next?
The administration is reportedly weighing alternatives, including Senator Roger Marshall of Kansas — a physician who recently left office.
The stakes are considerable. The FDA regulates products that account for a large share of U.S. consumer spending, from prescription drugs and medical devices to food safety standards. For dermatology specifically, that means the office that signs off on new therapeutics — biologics, topical agents, devices — continues operating under interim leadership.
The agency has now gone months without a Senate-confirmed permanent commissioner and has experienced significant staff reductions during that stretch. The withdrawal also adds to a pattern of turnover across senior health-agency leadership.
What does this change for clinicians and patients? In the short term, nothing structurally — review pipelines continue — but the question of who permanently leads the FDA remains open, and the speed of that answer could shape how quickly the department's broader policy agenda advances.
Source: ritzherald.com
Olivia Hart
Show full bio
News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.